2834 – Page 105 – China Stock Advice

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x September 30, 2012 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 5 EX-32.2]

By info| 2016-02-07T15:34:54+00:00 November 19th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 10-Q, 2012-11-19, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x September 30, 2012

[FORM 10-Q (Mark One) x September 30, 2012 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 5 EX-32.2]

By info| 2016-02-07T15:35:48+00:00 November 19th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 10-Q, 2012-11-19, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited Third Quarter 2012 Financial Results – Conference call scheduled for Thursday, November 15, 2012 at 8:00 AM EST– Beijing – November 15, 2012 – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China, announced today its unaudited financial results for the third quarter ended September 30, 2012. Third Quarter 2012 Financial Highlights (year-over-year comparisons] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F X ___ Form 40-F _________ SINOVAC BIOTECH LTD. Weidong Yin Chairman and Chief Executive Officer 6-K 1 v328746_6k.htm FORM 6-K]

By info| 2016-03-24T00:52:03+00:00 November 16th, 2012|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2012-11-16, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited Third Quarter 2012 Financial Results

[Sinovac Reports Unaudited Third Quarter 2012 Financial Results – Conference call scheduled for Thursday, November 15, 2012 at 8:00 AM EST– Beijing – November 15, 2012 – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China, announced today its unaudited financial results for the third quarter ended September 30, 2012. Third Quarter 2012 Financial Highlights (year-over-year comparisons] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F X ___ Form 40-F _________ SINOVAC BIOTECH LTD. Weidong Yin Chairman and Chief Executive Officer 6-K 1 v328746_6k.htm FORM 6-K]

By info| 2016-03-24T00:53:42+00:00 November 16th, 2012|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2012-11-16, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

BSPM [Biostar Pharmaceuticals,] NT 10-Q: (Original Filing)

[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 202 o o o (Check One): x o o For Period Ended: September 30, 2012 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]

By info| 2016-03-03T11:39:51+00:00 November 15th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 2012-11-15, 2834, BSPM, NT_10-Q, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals,] NT 10-Q: FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER:090678

[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER:090678 202 o o o (Check One): x o o For Period Ended:September 30, 2012 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall benstrued to imply that themmission has verified any informationntained herein.]

By info| 2016-02-07T15:37:39+00:00 November 15th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 2012-11-15, 2834, BSPM, NT_10-Q, PHARMACEUTICAL PREPARATIONS|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: (Original Filing)

[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Weibing Lu, Chief Executive Officer] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Bing Mei, Chief Financial Officer]

By info| 2016-03-01T04:25:03+00:00 November 14th, 2012|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 10-Q, 2012-11-14, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x September 30, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 14, 2012 President and Chief Executive Officer EX-32.1 4 cphi10qex321093012.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 14, 2012 (principal financial officer and principal accounting officer) EX-32.2 5 cphi10qex322093012.htm]

By info| 2016-03-03T17:36:00+00:00 November 14th, 2012|Categories: Chinese Stocks, CPHI, SEC Original|Tags: 0001106644, 10-Q, 2012-11-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q:

[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Weibing Lu, Chief Executive Officer] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Bing Mei, Chief Financial Officer]

By info| 2016-03-01T04:25:47+00:00 November 14th, 2012|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 10-Q, 2012-11-14, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x September 30, 2012

[FORM 10-Q (Mark One) x September 30, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 14, 2012 President and Chief Executive Officer EX-32.1 4 cphi10qex321093012.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 14, 2012 (principal financial officer and principal accounting officer) EX-32.2 5 cphi10qex322093012.htm]

By info| 2016-03-03T17:37:37+00:00 November 14th, 2012|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: 0001106644, 10-Q, 2012-11-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments